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Multimodal treatment was used in 23 (85%): chemotherapy and radiation
in 8 (34%), chemotherapy and surgery in 5 (21%), chemotherapy, surgery
and radiation in 10 (43%). Nine patients with non-axial disease and 5
patients with axial disease had surgery (p¼0.03). Median follow-up for
the treated patients was 27.5-months (Range:1-90).Out of 23 children
who received curative treatment-11(47%) were alive &well, 5 (21%) were
on treatment, 2 (0.08%) abandoned treatment & 4 (0.17%) had relapse/
refractory disease; one (0.04%) patient died from treatment related
toxicity. Five-year overall survival and event-free survival were 40% &
52%, respectively. Axial location (p¼0.27), metastatic disease (p¼0.74),
and lack of surgery (p¼0.34) were not statistically predictive of relapse/
progression, probably due to low numbers of patient and limited duration
of follow up.
Conclusions: In spite of a similar clinical proﬁle and disease stage, the
outcome of Ewings sarcoma in our patients simulates that reported in
Indian studies, however lags behind Western statistics. Reducing aban-
donment by tracking defaulters and providing support, using a uniform
protocol, and improving supportive care, were identiﬁed as plausible steps
to improve outcomes.ST-1_V1.2
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Background: Hepatoblastoma (HBL) is the most common primary liver
tumor in children. Metastatic disease at presentation, alphafetoprotein
(AFP) less than 100 ng/ml, PRETEXT IV, undifferentiated histology are usual
poor prognostic markers. Neoadjuvant chemotherapy with surgical
resection has led to increased survival of these patients
Aim: This single centre study assesses the outcome and the factors
affecting prognos is of children treated as per guidelines of SIOPEL3 in a
low middle income country (LMIC).
Materials & Methods: Forty children with HBL treated as per protocol
from Jan 2007 to Dec 2015 were analyzed. The diagnosis was established
by imaging, AFP and histology/cytology.
Results: 27 boys & 13 girls; median age 12 months (2-120) with a mean
symptom diagnosis interval (SDI) of 5.3 weeks (1-24) were diagnosed.
Multifocal involvement was seen in 7/40. Median AFP at diagnosis: 16500
ng/ml (3-406198). 2 had AFP less than 100 ng/ml. Mean platelet count at
diagnosis was 701375/cmm (95% CI 595510.80 to 807239.20).7 (17.5%)
had metastatic disease (6 lungs; 1 adrenal). PRETEXT: I-IV: 6, 13, 11 & 9.
Nineteen: high risk (HR) disease (7 with SDI more than 8 weeks) 13/40
defaulted/refused therapy. All cases received neoadjuvant chemotherapy.
3 deaths occurred prior to surgery. 25 underwent surgery; complete
resection (CR): 18/25 [14 : well; 3 relapsed, 1 died]. 7 cases subtotal
resection : 2 : well, 4 had persistant disease and 1 death.2/3 childrenwho
received salvage chemotherapy with Docetaxel had no response. HR
patients had a poorer outcome (p¼.012), more multifocal disease
(p¼.0395) and signiﬁcantly lower CR (p¼.0016) as compared to standard
risk patients. On comparing well Vs relapsed/residual disease cases;
there was no difference in AFP levels, volume reduction after neo-
adjuvant therapy, metastasis, & histopathology (p¼ns). Relapsed/resid-
ual disease was signiﬁcantly higher in those with higher mean age (24
mth Vs 12 mth); PRETEXT IV & multifocal disease (p¼0.02 & 0.04).
16 of 27 patients are presently well; median follow up being 48.3 months
(7-101).
Conclusion: 59 % (16/27) of cases whowere treated are well. 86%of SR HBL
had good outcome. Higher age at presentation, multifocality and high
PRETEXT was associated with poor outcome. HR patients had a longer SDI.
Docetaxel as a salvage therapy was not effective. Liver transplant, not
available at our centre, would have helped the children with incomplete
resection. Delayed referral and diagnosis remains a problem in LMIC's as
evident by greater SDI in those with HR disease.ST-1_V1.3
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Abstract
Background: Advances in chemotherapy, liver resection techniques and
pediatric liver transplantation have vastly improved survival in children
with hepatoblastoma (HB). These are best managed by a multidisciplinary
team in a setting where all treatment options are available. Until recently
this was difﬁcult to achieve in India.
Methods: Review of all children (< 16yrs) with HB treated in a pediatric
liver surgery & transplantation unit between Jan 2011 and July 2016. Data
regarding the clinical presentation, pre-operative management, surgical
treatment, postoperative course and outcomes was extracted from a pro-
spectively managed database.
Results: Thirty children were treated for HB during the study period.
Nine children were PRETEXT 4, 7 were PRETEXT 3, 13 were PRETEXT 2
and one was PRETEXT 1. All children received neoadjuvant chemo-
therapy before surgery followed by adjuvant chemotherapy. Nineteen
children had complete resection, while six underwent primary living
donor liver transplantation. There were 6 mortalities including 5 chil-
dren who poorly responded to chemotherapy with progressive tumor
extension. At a median follow-up of 30 months, two children who un-
derwent resection and one child who underwent liver transplant had
disease recurrence.
Conclusion: Improved outcomes can be achieved in childrenwith HB even
in countries with limited resources when they are managed by multidis-
ciplinary teams with expertise in pediatric oncology, liver resection and
liver transplantation.ST-1_V1.4
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Introduction: Medulloblastoma is the second most common primary
malignant brain tumour in children. We present the clinic-pathological
proﬁle of children seen in a pediatric hematology/Oncology unit over a
ten-year period.
Method: Clinical and laboratory data of children with medulloblastoma
who attended the pediatric hematology/oncology unit of CMC, Vellore
from 2004 to 2014 were retrieved from the medical records and reviewed.
Results: 76 children, 49 boys and 27 girls, with mean age at presentation
8.5±3.45 years. 7 were < 3 years and 22 were >10years. Headache (86%)
vomiting (79%) and ataxia (58%) were the common symptoms. The mean
duration from onset of symptoms to diagnosis was 2.7 ±2.2 months with
78% diagnosed within 3 months. All children presented to the neurosur-
gical team at ﬁrst visit. 30% required emergency CSF diversion procedure.
All children underwent upfront surgical excision; 30 had residual tumour
>1.5cm2. Risk stratiﬁcation based on age at presentation, volume of re-
sidual tumour and presence of metastatic disease, showed 43/76 to be in
the high risk category.
Histological classiﬁcation showed the following: classic 22 (37%), desmo-
plastic 19 (33%), medulloblastoma with extensive nodularity9 (16%), large
